Literature DB >> 11856814

Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X.

Rodney A Velliquette1, Richard J Koletsky, Paul Ernsberger.   

Abstract

Metabolic Syndrome X is a cluster of abnormalities including insulin resistance, hyperlipidemia, hypertension, and obesity. We sought to determine if excess plasma glucagon and free fatty acids (FFA) might contribute to the insulin resistance in the obese spontaneous hypertensive rat (SHROB), a unique animal model of leptin resistance and metabolic Syndrome X. SHROB were extremely hyperinsulinemic and mildly glucose intolerant compared with lean SHR. SHROB had elevated fasting plasma glucagon and FFA, and showed paradoxical responses to an oral glucose challenge, with increased glucagon at 30 and 60 min postchallenge (200% plus minus 45% and 91% plus minus 13%, respectively; n = 9). In lean SHR, glucagon was nearly unchanged by glucose loading (<30% increase, P > 0.05; n = 5). Plasma FFA were not affected by a glucose load in SHROB, whereas SHR showed a decrease of 40% plus minus 6% (n = 5--9). The I/G molar ratio changed in opposite directions in the two genotypes, with a decrease in SHROB at 30 and 60 min, in contrast to the appropriate increase at 30 and 60 min postchallenge in the lean SHR (P < 0.01; n = 5--9). Administration of 500 ng/kg exogenous glucagon to SHR raised glucagon 56% plus minus 5% to a level that was similar to fasting SHROB. This level of circulating glucagon was sufficient to elevate glucose and insulin during the 7 hr of observation (n = 9). Based on these results, we suggest that fasting hyperglucagonemia and impaired suppression of glucagon secretion and FFA in response to an oral glucose load may contribute to insulin resistance and glucose intolerance in the SHROB model of metabolic Syndrome X.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856814     DOI: 10.1177/153537020222700303

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  5 in total

1.  Therapeutic actions of allylmercaptocaptopril and captopril in a rat model of metabolic syndrome.

Authors:  Paul Ernsberger; Janean L Johnson; Talma Rosenthal; David Mirelman; Richard J Koletsky
Journal:  Am J Hypertens       Date:  2007-08       Impact factor: 2.689

2.  The extracellular cAMP-adenosine pathway regulates expression of renal D1 dopamine receptors in diabetic rats.

Authors:  Eldo V Kuzhikandathil; Leslie Clark; Ying Li
Journal:  J Biol Chem       Date:  2011-07-29       Impact factor: 5.157

3.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis.

Authors:  Eusebio Chiefari; Francesco Paonessa; Stefania Iiritano; Ilaria Le Pera; Dario Palmieri; Giuseppe Brunetti; Angelo Lupo; Vittorio Colantuoni; Daniela Foti; Elio Gulletta; Giovambattista De Sarro; Alfredo Fusco; Antonio Brunetti
Journal:  BMC Biol       Date:  2009-05-21       Impact factor: 7.431

5.  Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.

Authors:  Barbora Mikulášková; Martina Holubová; Veronika Pražienková; Jana Zemenová; Lucie Hrubá; Martin Haluzík; Blanka Železná; Jaroslav Kuneš; Lenka Maletínská
Journal:  Nutr Diabetes       Date:  2018-01-16       Impact factor: 5.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.